{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:20:33Z","timestamp":1787800833669,"version":"build-2784847793"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,27]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In the FLOW trial (Evaluate Renal Function with Semaglutide Once-Weekly; ClinicalTrials.gov, NCT03819153), once-weekly subcutaneous semaglutide 1.0 mg versus placebo reduced the risk of major kidney, cardiovascular (CV) and mortality outcomes in participants with type 2 diabetes (T2D) and chronic kidney disease (CKD). This pre-specified analysis assesses the impact of semaglutide on risks of serious infections and coronavirus disease 2019 (COVID-19) in the FLOW trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The main outcome was a three-component composite [time from randomization to first infection serious adverse event (SAE), first hospitalization due to infection, or all-cause death]. Other outcomes included all infection SAEs, COVID-19 adverse events, COVID-19 SAEs, death due to infection and death concurrent with a COVID-19 SAE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Semaglutide reduced the risk of the main outcome versus placebo [hazard ratio (HR) (95% confidence interval) 0.79 (0.69\u20130.89); P\u00a0=\u00a0.0002]. This risk reduction was greater in subgroups with baseline hemoglobin A1c &amp;gt;8% [HR 0.63 (0.52\u20130.76)] versus \u22648% [HR 0.93 (0.79\u20131.11); Pinteraction\u00a0=\u00a0.0027], and urine albumin-to-creatinine ratio (UACR) \u22652000\u00a0mg\/g [HR 0.53 (0.39\u20130.72)] versus UACR &amp;lt;100\u00a0mg\/g [HR 0.90 (0.58\u20131.39); Pinteraction\u00a0=\u00a0.0367]. The semaglutide group had a lower rate of infection SAEs (17.9% versus 21.3%; P\u00a0=\u00a0.0070), COVID-19 SAEs (6.7% versus 8.8%; P\u00a0=\u00a0.0155), COVID-19 adverse events (20.3% versus 22.9%; P\u00a0=\u00a0.0190) and hospitalization due to infection (17.5% versus 20.4%; P\u00a0=\u00a0.015).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Semaglutide reduced risks of infection SAEs, hospitalization due to infection, and all-cause death with greater benefit among those with poorer glycemic control and greater baseline albuminuria. These findings support potential clinical benefits of semaglutide beyond kidney, CV and metabolic outcomes in high-risk patients with T2D and CKD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfag036","type":"journal-article","created":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T12:30:12Z","timestamp":1771763412000},"page":"1696-1708","source":"Crossref","is-referenced-by-count":3,"title":["Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial"],"prefix":"10.1093","volume":"41","author":[{"given":"Brian","family":"Rayner","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, Groote Schuur Hospital and University of Cape Town , Cape Town ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W","family":"Mahaffey","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine Department of Medicine, Stanford Center for Clinical Research, , Stanford, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes F E","family":"Mann","sequence":"additional","affiliation":[{"name":"KfH Kidney Centre , M\u00fcnchen ,","place":["Germany"]},{"name":"University Hospital, Friedrich-Alexander University , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E","family":"Pratley","sequence":"additional","affiliation":[{"name":"AdventHealth Translational Research Institute , Orlando, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1531-4294","authenticated-orcid":false,"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center Copenhagen , Herlev ,","place":["Denmark"]},{"name":"University of Copenhagen Department of Clinical Medicine, , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Belmar","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidrun","family":"Bosch-Traberg","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Kleist","family":"Jeppesen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh Chau","family":"Tran","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7514-156X","authenticated-orcid":false,"given":"Gil","family":"Chernin","sequence":"additional","affiliation":[{"name":"Kaplan Medical Center, Hebrew University of Jerusalem , Rehovot ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2235-0103","authenticated-orcid":false,"given":"Katherine R","family":"Tuttle","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Washington School of Medicine , Seattle, WA ,","place":["USA"]},{"name":"Providence Medical Research Center, Providence Inland Northwest Health , Spokane, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"2026082623121832900_bib1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","journal-title":"Lancet"},{"key":"2026082623121832900_bib2","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2026082623121832900_bib3","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1016\/S2214-109X(23)00570-3","article-title":"An update on the global disparities in kidney disease burden and care across world countries and regions","volume":"12","author":"Bello","year":"2024","journal-title":"Lancet Glob Health"},{"key":"2026082623121832900_bib4","doi-asserted-by":"publisher","first-page":"e0158765","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease\u2014a systematic review and meta-analysis","volume":"11","author":"Hill","year":"2016","journal-title":"PLoS One"},{"key":"2026082623121832900_bib5","doi-asserted-by":"publisher","first-page":"e000154","DOI":"10.1136\/bmjdrc-2015-000154","article-title":"Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007-2012","volume":"4","author":"Wu","year":"2016","journal-title":"BMJ Open Diab Res Care"},{"key":"2026082623121832900_bib6","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1080\/00325481.2021.2009726","article-title":"Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations","volume":"134","author":"Shubrook","year":"2022","journal-title":"Postgrad Med"},{"key":"2026082623121832900_bib7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2337\/cd22-0110","article-title":"Perspectives on chronic kidney disease with type 2 diabetes and risk management: practical viewpoints and a paradigm shift using a pillar approach","volume":"41","author":"Morales","year":"2023","journal-title":"Clin Diabetes"},{"key":"2026082623121832900_bib8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1053\/j.ajkd.2014.11.027","article-title":"CKD and the risk of acute, community-acquired infections among older people with diabetes mellitus: a retrospective cohort study using electronic health records","volume":"66","author":"McDonald","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2026082623121832900_bib9","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2026082623121832900_bib10","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1007\/s00125-024-06102-x","article-title":"Diabetes and infection: review of the epidemiology, mechanisms and principles of treatment","volume":"67","author":"Holt","year":"2024","journal-title":"Diabetologia"},{"key":"2026082623121832900_bib11","doi-asserted-by":"publisher","first-page":"e002299","DOI":"10.1136\/bmjdrc-2021-002299","article-title":"Evaluation and management of COVID-19-related severity in people with type 2 diabetes","volume":"9","author":"Wang","year":"2021","journal-title":"BMJ Open Diab Res Care"},{"key":"2026082623121832900_bib12","author":"Zhou"},{"key":"2026082623121832900_bib13","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2337\/dc17-2131","article-title":"Risk of infection in type 1 and type 2 diabetes compared with the general population: a matched cohort study","volume":"41","author":"Carey","year":"2018","journal-title":"Diabetes Care"},{"key":"2026082623121832900_bib14","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.kint.2016.07.013","article-title":"Infection in advanced chronic kidney disease leads to increased risk of cardiovascular events, end-stage kidney-disease and mortality","volume":"90","author":"Hassan","year":"2016","journal-title":"Kidney Int"},{"key":"2026082623121832900_bib15","doi-asserted-by":"publisher","first-page":"649525","DOI":"10.3389\/fendo.2021.649525","article-title":"COVID-19 and diabetes: understanding the interrelationship and risks for a severe course","volume":"12","author":"Landstra","year":"2021","journal-title":"Front Endocrinol"},{"key":"2026082623121832900_bib16","author":"US Centers for Disease Control and Prevention","journal-title":"Underlying Conditions and the Higher Risk for Severe COVID-19"},{"key":"2026082623121832900_bib17","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.cmet.2020.04.021","article-title":"Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes","volume":"31","author":"Zhu","year":"2020","journal-title":"Cell Metab"},{"key":"2026082623121832900_bib18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2026082623121832900_bib19","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","article-title":"The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease","volume":"38","author":"Rossing","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026082623121832900_bib20","doi-asserted-by":"publisher","first-page":"ehac544.1053","DOI":"10.1093\/eurheartj\/ehac544.1053","article-title":"Causes of death in patients with chronic kidney disease: insights from the ASCEND-D and ASCEND-ND cardiovascular outcomes trials","volume":"43","author":"Singh","year":"2022","journal-title":"Eur Heart J"},{"key":"2026082623121832900_bib21","doi-asserted-by":"publisher","first-page":"327","DOI":"10.4103\/ijn.ijn_293_21","article-title":"Diabetes and mortality among patients with chronic kidney disease and COVID-19: a systematic review, meta-analysis, and meta-regression","volume":"32","author":"Iryaningrum","year":"2022","journal-title":"Indian J Nephrol"},{"key":"2026082623121832900_bib22","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1093\/ckj\/sfac168","article-title":"Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohort","volume":"15","author":"Pollock","year":"2022","journal-title":"Clin Kidney J"},{"key":"2026082623121832900_bib23","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13098-023-01118-6","article-title":"The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials","volume":"15","author":"Yu","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"2026082623121832900_bib24","doi-asserted-by":"publisher","first-page":"e221169","DOI":"10.1001\/jamanetworkopen.2022.1169","article-title":"Association of glucagon-like peptide-1 receptor agonist vs dipeptidyl peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease","volume":"5","author":"Chen","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026082623121832900_bib25","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cmet.2023.11.009","article-title":"Central glucagon-like peptide 1 receptor activation inhibits toll-like receptor agonist-induced inflammation","volume":"36","author":"Wong","year":"2024","journal-title":"Cell Metab"},{"key":"2026082623121832900_bib26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/3094642","article-title":"Anti-inflammatory effects of GLP-1-based therapies beyond glucose control","volume":"2016","author":"Lee","year":"2016","journal-title":"Mediators Inflamm"},{"key":"2026082623121832900_bib27","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.jacc.2024.08.007","article-title":"The effect of semaglutide on mortality and COVID-19-related deaths: an analysis from the SELECT trial","volume":"84","author":"Scirica","year":"2024","journal-title":"J Am Coll Cardiol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag036\/67073037\/gfag036.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/9\/1696\/67073037\/gfag036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/9\/1696\/67073037\/gfag036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:12:36Z","timestamp":1787800356000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/9\/1696\/8494850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,2,23]]},"published-print":{"date-parts":[[2026,8,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfag036","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,2,23]]}}}